Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est
The inclusion of NAC and selenium further enhances immune defense, helping your body respond more effectively to infections and inflammation
i tng s dng
Scott, K
Oral options typically carry lower manufacturing costs and eliminate the expenses associated with injection devices, cold chain shipping, and medical waste disposal
US$ 29.81
US$ 26.35
US$ 21.63
